Zymeworks Inc., a clinical-stage biotechnology company, has announced the appointment of Greg Ciongoli and Robert E. Landry to its Board of Directors, effective August 10, 2025. Both appointees will also serve as members of the audit committee. This change comes as part of Zymeworks' strategy to advance its development programs and support its long-term growth objectives. Troy Cox, a board member since 2019, has stepped down.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zymeworks Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9509620-en) on August 11, 2025, and is solely responsible for the information contained therein.